{{Rsnum
|rsid=3132453
|Gene=BAT2
|Chromosome=6
|position=31636267
|Orientation=minus
|GMAF=0.02755
|Gene_s=PRRC2A
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 0.9 | 14.3 | 84.8
| HCB | 0.0 | 0.0 | 100.0
| JPT | 0.0 | 1.8 | 98.2
| YRI | 0.0 | 0.7 | 99.3
| ASW | 0.0 | 1.8 | 98.2
| CHB | 0.0 | 0.0 | 100.0
| CHD | 0.0 | 1.9 | 98.1
| GIH | 0.0 | 1.0 | 99.0
| LWK | 0.0 | 0.9 | 99.1
| MEX | 0.0 | 3.6 | 96.4
| MKK | 0.0 | 0.6 | 99.4
| TSI | 1.0 | 9.9 | 89.1
| HapMapRevision=28
}}

[[rs3132453]], a SNP in the [[BAT2]] gene also known as V1883L, is associated with reduced risk for developing [[Non-Hodgkin Lymphoma]] based on a study of 458 patients. The odds ratio is 0.64 (CI: 0.45-0.90, p<0.01). {{PMID|17827388|OA=1
}}

{{PMID Auto
|PMID=19143815
|Title=MHC fine mapping of human type 1 diabetes using the T1DGC data.
|OA=1
}}

{{GET Evidence
|gene=PRRC2A
|aa_change=Leu1895Val
|aa_change_short=L1895V
|impact=not reviewed
|qualified_impact=Insufficiently evaluated not reviewed
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs3132453
|n_genomes=54
|n_genomes_annotated=0
|n_haplomes=104
|n_articles=0
|n_articles_annotated=0
|nblosum100=0
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=23047821
|Title=PRRC2A and BCL2L11 gene variants influence risk of non-Hodgkin lymphoma: results from the InterLymph consortium.
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}